Company Performance - Oncobiologics reported a quarterly loss of $0.44 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, but an improvement from a loss of $0.83 per share a year ago, indicating a year-over-year improvement in losses [1] - The company posted revenues of $1.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 40.98%, compared to zero revenues a year ago [2] - Over the last four quarters, Oncobiologics has surpassed consensus EPS estimates two times [2] Stock Performance - Oncobiologics shares have increased by approximately 12.7% since the beginning of the year, outperforming the S&P 500's gain of 10% [3] - The current Zacks Rank for Oncobiologics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.33 on revenues of $5.78 million, and for the current fiscal year, it is -$1.89 on revenues of $6.42 million [7] - The outlook for the Medical - Biomedical and Genetics industry, in which Oncobiologics operates, is currently in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - Absci Corporation (ABSI) reported a quarterly loss of $0.24 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.19, indicating a negative earnings surprise of -26.32% [1] Financial Performance - The company posted revenues of $0.59 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 74.44%, compared to revenues of $1.27 million in the same quarter last year [2] - Over the last four quarters, the company has only surpassed consensus EPS estimates once [2] Stock Performance - Absci Corporation shares have increased by approximately 8.8% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $9.2 million, and for the current fiscal year, it is -$0.68 on revenues of $15.19 million [7] - The estimate revisions trend for Absci Corporation was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Absci Corporation belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]

Core Insights - Clearside Biomedical, Inc. reported a quarterly loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a loss of $0.12, marking a 50% earnings surprise [1] - The company achieved revenues of $0.49 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 87.07%, compared to revenues of $0.09 million a year ago [2] - The stock has underperformed, losing approximately 59.7% since the beginning of the year, while the S&P 500 has gained 7.8% [3] Financial Performance - Over the last four quarters, Clearside Biomedical has surpassed consensus EPS estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $0.26 million, and for the current fiscal year, it is -$0.38 on revenues of $3.22 million [7] Market Outlook - The company's earnings outlook is crucial for assessing future stock performance, with a favorable trend in estimate revisions leading to a Zacks Rank 2 (Buy) [6] - The Medical - Biomedical and Genetics industry is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8]

Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.12%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.41 per share when it actually produced earnings of $0.12, delivering a surprise of -70.73%.Over the last four quarters, the comp ...

Company Performance - MaxCyte, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.09 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $8.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 14.93%, and down from $10.43 million in the same quarter last year [2] - Over the last four quarters, MaxCyte has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - MaxCyte shares have lost approximately 50.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for MaxCyte is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.09 on revenues of $10.4 million, and for the current fiscal year, it is -$0.38 on revenues of $41.2 million [7] - The estimate revisions trend for MaxCyte was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - MaxCyte operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - Adma Biologics reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, and showing an increase from $0.13 per share a year ago, indicating a positive earnings surprise of +7.14% [1] Financial Performance - The company achieved revenues of $121.98 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.73% and up from $107.19 million in the same quarter last year [2] - Over the last four quarters, Adma Biologics has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Adma Biologics shares have increased approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.17 on revenues of $130.7 million, and for the current fiscal year, it is $0.61 on revenues of $505.8 million [7] - The company's earnings outlook will be crucial for assessing future stock performance, especially in light of recent earnings report and management commentary [4][6] Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8]

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $2.35. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +34.89%. A quarter ago, it was expected that this company would post a loss of $2.8 per share when it actually produced a loss of $2.11, delivering a surprise of +24.64%.Over the last four quarters, the compa ...

Company Performance - Arvinas, Inc. reported a quarterly loss of $0.84 per share, which was better than the Zacks Consensus Estimate of a loss of $0.87, but worse than a loss of $0.49 per share a year ago, indicating an earnings surprise of +3.45% [1] - The company posted revenues of $22.4 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 53.28%, and a significant decline from year-ago revenues of $76.5 million [2] - Over the last four quarters, Arvinas has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Outlook - Arvinas shares have declined approximately 60.3% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.75 on revenues of $41.04 million, and for the current fiscal year, it is -$1.50 on revenues of $294.99 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Arvinas belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Techne (TECH) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.00%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.51 per share when it actually produced earnings of $0.56, delivering a surprise of +9.8%.Over the la ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%.Over the last four quarters, the ...